Neurocrine Bioscience Stock
€135.75
Your prediction

sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Neurocrine
sharewise wants to provide you with the best news and tools for Neurocrine, so we directly link to the best financial data sources.
Financials
News
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
Key Points
- Interested in Ionis Pharmaceuticals, Inc.? Here are five stocks we like better.
- Ionis Pharmaceuticals said TRYNGOLZA could become a more than $3 billion U.S. product in severe
Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement
Soleno Therapeutics (NASDAQ:SLNO), a rare-disease drug developer, closed Monday at $52.26, up 32.31%. The stock’s move reflects Neurocrine Biosciences’ (NASDAQ:NBIX) $53-per-share all-cash
Why Soleno Therapeutics Stock Rocketed Higher on Monday
On news that Soleno Therapeutics (NASDAQ: SLNO) has agreed to be acquired, investors piled into the company's shares on Monday. This left the commercial-stage biotech with a juicy 32% gain on the


